SCHEMBL6237621

SCHEMBL6237621

CC(C)(C)OC(=O)NC(CS)C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
HTT P42858 1/20 0.47
CTSK P43235 10/20 0.46
CTSS P25774 7/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CTSL P07711 1/20 0.44
CTSB P07858 1/20 0.44
HDAC4 P56524 2/20 0.43
HDAC1 Q13547 2/20 0.43
HDAC6 Q9UBN7 1/20 0.43
CYP2D6 P10635 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7079252 1.00 CYP1A2 (0.47) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL295886 0.91 CYP1A2 (0.46) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL1341495 0.91 CYP1A2 (0.46) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL3819517 0.91 CYP1A2 (0.46) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL1455923 0.88 CYP1A2 (0.61) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL1455920 0.88 CYP1A2 (0.61) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL474893 0.86 HDAC4 (0.47) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL30788769 0.86 HDAC4 (0.47) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL474895 0.86 HDAC4 (0.47) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL377348 0.85 MAPT (0.55) CYP1A2CYP2C9CYP2C19HTTCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114585637-A MASP inhibiting compounds and uses thereof 拜耳公司 2022-06-03 CN disclosed
CN-113784710-A Compounds for the treatment of hypertension or heart failure and compositions comprising the same 量子基因公司 2021-12-10 CN disclosed
WO-2020225095-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2020-11-12 WO disclosed
CN-107033186-B Posaconazole derivatives, pharmaceutical compositions and uses thereof 武汉朗来科技发展有限公司 2020-06-09 CN disclosed
US-20170267689-A1 STIMULI-SWITCHABLE MOIETIES, MONOMERS AND POLYMERS INCORPORATING STIMULI-SWITCHABLE MOIETIES, AND METHODS OF MAKING AND USING SAME THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2017-09-21 US disclosed
US-20170267689-A1 STIMULI-SWITCHABLE MOIETIES, MONOMERS AND POLYMERS INCORPORATING STIMULI-SWITCHABLE MOIETIES, AND METHODS OF MAKING AND USING SAME THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2017-09-21 US disclosed
WO-2005005377-A1 (2R, 5R)-6N-(1-IMINOETHYL)-2,6-DIAMINO-5-METHYL-4-THIOHEXANOIC ACID; SALTS THEREOF; A PROCESS FOR THEIR PREPARATION; PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDECINE GLAXO GROUP LIMITED (GB) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267689-A1 STIMULI-SWITCHABLE MOIETIES, MONOMERS AND POLYMERS INCORPORATING STIMULI-SWITCHABLE MOIETIES, AND METHODS OF MAKING AND USING SAME PASK, PAM, PTMS CYP1A2 4073/4885CYP2C9 4019/4885CYP2C19 2465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.